Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Glioblastoma × Cell Count × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Epstein-Barr Virus Infections 2 Cytomegalovirus Infections 2 Adenoviridae Infections 2 Neoplasms 1 Immunologic Deficiency Syndromes 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 34 Radiotherapy 14 pembrolizumab 10 Magnetic Resonance Spectroscopy 10 Lomustine 9 Bevacizumab 9 Specimen Handling 8 Radiation 5 Cyclophosphamide 5 fludarabine 4 Nivolumab 4 Transurethral Resection of Bladder 3 Ipilimumab 3 Aminolevulinic Acid 3 regorafenib 2 olaparib 2 fluciclovine F-18 2 atezolizumab 2 antisecretory factor 2 abemaciclib 2 Surgical Procedures, Operative 2 Standard of Care 2 Restraint, Physical 2 Palliative Care 2 ONC206 2 Leukapheresis 2 Interleukin-2 2 Genetic Therapy 2 GDC-0084 2 Filgrastim 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07144735 2025-08-27

ABOUT

Peking University Third Hospital

Phase NA Recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡